Jenni Golletti
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 119 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,310 and has fallen 92.5% since, to $98 in 2025.
Across 119 payments — averaging $23.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$431
- AbbVie$409
- GSK$362
- Abbott$222
- Novartis$216
- Amgen$178
- plus $992 from 18 others
What the payments were for
- Food & beverage$2,810100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 24 | $431 |
| AbbVie | 27 | $409 |
| GSK | 12 | $362 |
| Abbott | 12 | $222 |
| Novartis | 13 | $216 |
| Amgen | 4 | $178 |
| Bayer | 1 | $130 |
| Biotissue Holdings Inc. | 1 | $125 |
| Biohaven Pharmaceuticals, Inc. | 1 | $124 |
| Teva Pharmaceuticals USA, Inc. | 1 | $124 |
| AstraZeneca | 4 | $75 |
| Boston Scientific | 2 | $65 |
| Medtronic | 1 | $50 |
| Biogen | 2 | $47 |
| Pfizer | 2 | $42 |
| Lilly USA, LLC | 2 | $37 |
| Phadia US Inc. | 2 | $32 |
| Johnson & Johnson | 2 | $32 |
| Boehringer Ingelheim | 1 | $27 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Merck | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Dexcom, Inc. | 1 | $15 |
| Currax Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$130
- Otezla$125
- Prokera$125
- AmnioGraft$125
- NURTEC ODT$124
- AUSTEDO$124
- TRELEGY ELLIPTA$122
How this compares
$2,810 in reported general payments places this provider in the 85th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 69 | $65,986 |
| OzempicSemaglutide | 47 | $49,396 |
| FarxigaDapagliflozin Propanediol | 61 | $42,554 |
| MounjaroTirzepatide | 34 | $41,048 |
| JardianceEmpagliflozin | 34 | $36,115 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 32 | $31,367 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 26 | $28,734 |
| TrulicityDulaglutide | 21 | $19,715 |
| JanuviaSitagliptin Phosphate | 20 | $13,804 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $7,161 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 20 | $6,102 |
| OxycontinOxycodone Hcl | 12 | $4,722 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 20 | $4,193 |
| Rosuvastatin Calcium | 176 | $3,107 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 18 | $2,736 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere | $75 | $73,92193 claims |
| PfizerEliquis, Abrysvo | $42 | $72,08889 claims |
| Lilly USA, LLCMounjaro, Trulicity | $37 | $60,76355 claims |
| Novo NordiskOzempic | $431 | $49,39647 claims |
| Boehringer IngelheimJardiance | $27 | $36,11534 claims |
| GSKTrelegy Ellipta, Shingrix | $362 | $32,92746 claims |
| MerckJanuvia | $18 | $13,80420 claims |
| AbbVieSynthroid | $409 | $83514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 14,618 family providers in Florida.
Other family in Miami
- Patrick SzarazMiami$327K
- Yamila MelendezMiami$212K
- Suzan RosenMiami$129K
- Felipe NovoaMiami$110K
- Pamela DudkiewiczMiami$89K
- Stacy FeemsterMiami$51K
- Estrella Moreno RodriguezMiami$30K
- Lewis HarringtonTampa$954K
- Danielle PharesFt Lauderdale$713K
- Donna OrtizOrlando$417K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.